Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular Events Andres J. Yarur, MD, Amar R. Deshpande, MD, David M. Pechman,

Slides:



Advertisements
Similar presentations
Inappropriate clopidogrel adherence explains stent related adverse outcomes Leonardo Tamariz, MD, MPH University of Miami.
Advertisements

Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.
Association of C-Reactive Protein and Acute Myocardial Infarction in HIV-Infected Patients Virginia A. Triant, MD, MPH, James B. Meigs, MD, MPH, and Steven.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis R2 이 홍 주 Am J Gastroenterol 2009 ; 104 : 673 ~ 678.
Cardiovascular and Gastrointestinal Outcomes in Clopidogrel Users on Proton Pump Inhibitors: Results of a Large Dutch Cohort Study 소화기 내과 R1 박지윤 Ofke S.
Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis The Annals of the.
Insights from a Contemporary STEMI Prospective Registry
R1. 이용석 / modulator pf. 동석호. Introduction Acute pancreatitis(AP) ▫most common disease that affects the pancreas ▫incidence of AP varies globally, affecting.
Dr John Cox Diabetes in Primary Care Conference Cork
An analysis of 22,672 patients from the CLARIFY registry
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
From ESH 2016 | LB 3: Davide Agnoletti, MD
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Quality of life as predictor for the development of.
History Of Atrial Fibrillation In A First-Degree Relative
The Plasma Concentrations of Atorvastatin and its Active Metabolites in Relation to the Dose in Stable Coronary Artery Disease Patients at a Tertiary Referral.
The role of unknown risk factors in coronary heart disease
Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study Kirchgesner J, et al. Gut 2017;0:1–8.
Results from the intermountain heart collaborative study
Annals of Internal Medicine
undetectable (undetectable-6.25)
. Troponin limit of detection plus cardiac risk stratification scores for the exclusion of myocardial infarction and 30-day adverse cardiac events in ED.
Work disability in inflammatory bowel disease
Ulcerative Colitis (UC)-Associated Colorectal Cancer (CRC) Patients Who Receives Colorectal Surgery More Likely Receive Blood Transfusion Than Crohn’s.
Contribution of Oxidized Low Density Lipoprotein and Nitric Oxide in the Pathogenesis of Early Onset Acute Myocardial Infarction in Egyptian population.
Patient populations by study group figure 10
HOPE: Heart Outcomes Prevention Evaluation study
Clinical need for determination of vulnerable plaques
Alina M. Allen MD, Patrick S. Kamath MD, Joseph J. Larson,
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Differences by HIV Serostatus in Coronary Artery Disease.
Figure 2.1 First-year hospital admission rates among incident dialysis patients, by annual & monthly cohorts Patients aged 18 years or older. Peer Report Dialysis.
Andre Lamy on behalf of the COMPASS Investigators
Influence of Body Mass Index on Long-Term Survival After Cardiac Catheterization  Barak Zafrir, MD, Ronen Jaffe, MD, Ronen Rubinshtein, MD, Basheer Karkabi,
J.Livie1, E.Goodall1, M.Wilson2,C.Payne2 Department of Surgery2
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Steroid Exposure, Acute Coronary Syndrome, and Inflammatory Bowel Disease: Insights into the Inflammatory Milieu  Pearl Zakroysky, MPH, Wai-ee Thai, MD,
Presenter: Wen-Ching Lan Date: 2018/08/01
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
The following slides highlight a report on a presentation at the Canadian Cardiovascular Congress held in Toronto, Ontario from October 24 to 29, 2003.
European Heart Association Journal 2007 April
The Prevalence of and Contributed Risk Factors of Cardiovascular Diseases among People with Spinal Cord Injury: A Retrospective Study Ramzi Alajam.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Giuseppe Biondi Zoccai, MD
Dysfunctional Uterine Activity in Labour and Premature Adverse Cardiac Events: Population-Based Cohort Study  Alyssa Kahane, BSc, Alison L. Park, MSc,
Impact of Platelet Reactivity Following Clopidogrel Administration
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
DECLARE-TIMI 58.
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Correlation between endothelial function and hypertension
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Flow chart of the cohort selection for the study
Cancer is not a risk factor for bullous pemphigoid
Risk factors for postoperative infection after lower gastrointestinal surgery in patients with inflammatory bowel disease: Findings from a large epidemiological.
Presentation transcript:

Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular Events Andres J. Yarur, MD, Amar R. Deshpande, MD, David M. Pechman, BS, Leonardo Tamariz, MD, MPH, Maria T. Abreu, MD and Daniel A. Sussman, MD Am J Gastroenterol 2011; 106: Hyun Hee Jae

Introduction  Inflammatory bowel disease  Several extraintestinal manifestations  Chronic inflammation  Hypercoagulable states  Several inflammatory mediators  CRP, TNF-a, CD40 ligand etc…  In both IBD and atherosclerosis

Introduction  Patients with IBD  A higher risk of developing early atherosclerosis  Increased carotid intima – media thickness  No definitive studies  Incidence of coronary artery disease in IBD patients

Introduction  Hypothesis in this study  Patients with IBD  A higher rate of cardiovascular events than the general outpatient population  The rate of CAD : Traditional and nontraditional cardiovascular risk factors

Methods  Retrospective longitudinal cohort study with matched controls  Medical records review

Methods  Patients  Resided in the state of Florida  >18 years of age  Medical care at Jackson Memorial Hospital in Miami, Florida  Embraced all patients with either Crohn’s disease or ulcerative colitis  Between January 1995 and December 2009  Unexposed group  At least twice yearly in the health maintenance clinic of the same institution  For each patient with IBD, two control subjects  Matching for age, gender, and city of residence

Methods  Traditional risk factors  Hypertension, diabetes mellitus, smoking status, dyslipidemia, family histoly of CAD, chronic kidney disease, obesity  Defined by the established diagnostic criteria  Nontraditional risk factors  WBC count, hemoglobin, platelet count, ESR, CRP  Steroid exposure  >90 days, <90 days  >20mg, <20mg

Methods  Outcomes  Primary outcome  The development of a CAD event  Acute coronary syndrome (unstable angina and MI)  In the IBD subgroup – at least 12 months after the diagnosis of IBD  Secondary outcome  The development of heart failure and the need for percutaneous or surgical revascularization

Results  Study population  356 patients with IBD  173 : crohn’s disease  183 : ulcerative colitis  712 matched non-IBD controls  Mean time of follow-up  53 months for the IBD subjects  51 months for the non-IBD subjects

Table 1. Baseline cardiovascular and inflammatory risk factors in IBD cases and controls

Table 3. Risk of CAD in IBD and non-IBD patients

Table 4. Development of combined CAD events by age

Table 5. Multivariate influence of CV risk factors on total CAD events

Figure 1. Impact of traditional CV risk factors on combined CAD events

Conclusion  Increased incidence of CAD events in IBD pts.  despite having a lower burden of traditional risk factors  Traditional risk factors  A lower impact on CAD development in the IBD group  Further investigation  How nontraditional risk factors in IBD pts. Change CAD risk

Table 2. Predictor factors and outcomes stratified by type of IBD